GSE173201 cisplatin 2 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE173201_cisplatin_2_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE173201_cisplatin_2_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE173201_cisplatin_2_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE173201_cisplatin_2_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 1

Gene

small nucleolar RNA host gene 5

Gene

double homeobox A pseudogene 8

Gene

small nucleolar RNA host gene 15

Gene

small nucleolar RNA host gene 7

Gene

small nucleolar RNA host gene 12

Gene

p53 upregulated regulator of p53 levels

Gene

long intergenic non-protein coding RNA 839

Gene

NSUN5 pseudogene 1

Gene

TALAM1 transcript, MALAT1 antisense RNA

  • Gene

    small nucleolar RNA host gene 1


  • Gene

    small nucleolar RNA host gene 5


  • Gene

    double homeobox A pseudogene 8


  • Gene

    small nucleolar RNA host gene 15


  • Gene

    small nucleolar RNA host gene 7


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    p53 upregulated regulator of p53 levels


  • Gene

    long intergenic non-protein coding RNA 839


  • Gene

    NSUN5 pseudogene 1


  • Gene

    TALAM1 transcript, MALAT1 antisense RNA

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.